HER2-Negative Breast Cancer - Current and Future Players

HER2-Negative Breast Cancer - Current and Future Players

  • Products Id :- GDHC1063FPR
  • |
  • Pages: 96
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

HER2-Negative Breast Cancer - Current and Future Players


GlobalData has released its pharma report, "HER2-Negative Breast Cancer - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key companies shaping and driving the global Insomnia market. The report provides insight into the competitive Insomnia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


- Investigation of current and future market competition for HER2-Negative Breast Cancer

- Competitor assessment

- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

- Strategic assessment of HER2-Negative Breast Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving HER2-Negative Breast Cancer market

- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

- What's the next big thing in the global HER2-Negative Breast Cancer market landscape? Identify, understand and capitalize

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Catalyst 6

2.2 Related Reports 6

2.3 Upcoming Related Reports 7

3 Market Outlook 8

3.1 Global Markets 8

3.1.1 Forecast 8

3.1.2 Drivers and Barriers - Global Issues 14

4 Current and Future Players 16

4.1 Overview 16

4.2 Trends in Corporate Strategy 18

4.3 Company Profiles 21

4.3.1 AstraZeneca 21

4.3.2 Bristol-Myers Squibb 22

4.3.3 Eli Lilly 24

4.3.4 Pfizer 25

4.3.5 Novartis/GlaxoSmithKline 28

5 Appendix 30

5.1 Bibliography 30

5.2 Abbreviations 57

5.3 Methodology 65

5.4 Forecasting Methodology 65

5.4.1 Diagnosed HER2-Negative Breast Cancer Patients 65

5.4.2 Percentage of Drug-Treated Patients 66

5.4.3 Drugs Included in Each Therapeutic Class 66

5.4.4 Launch and Patent Expiry Dates 67

5.4.5 General Pricing Assumptions 68

5.4.6 Individual Drug Assumptions 70

5.4.7 Generic Erosion 78

5.4.8 Pricing of Pipeline Agents 78

5.5 Primary Research - KOLs Interviewed for This Report 89

5.6 Primary Research - High-Prescriber Survey 91

5.7 About the Authors 92

5.7.1 Analyst 92

5.7.2 Director of Oncology 92

5.7.3 Epidemiologist 93

5.7.4 Director of Epidemiology 93

5.7.5 Global Head of Healthcare 94

5.8 About GlobalData 95

5.9 Disclaimer 95

1.2 List of Figures

Figure 1: Global Sales ($m) for HER2-Negative Breast Cancer by Region, 2013-2023 12

Figure 2: Global Sales for HER2-Negative Breast Cancer by Drug, 2013-2022 13

Figure 3: Global Sales ($m) of Branded Products for HER2-Negative Breast Cancer by Company*, 2013-2023 17

Figure 4: Company Portfolio Gap Analysis in HER2-Negative Breast Cancer 2013-2023 18

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for HER2-Negative Breast Cancer, 2013-2023 11

Table 2: Global HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023 14

Table 3: AstraZeneca's, Breast Cancer Portfolio Assessment, 2014 22

Table 4: AstraZeneca SWOT Analysis, 2014 22

Table 5: BMS' Breast Cancer Portfolio Assessment, 2014 24

Table 6: BMS SWOT Analysis, 2014 24

Table 7: Eli Lilly SWOT Analysis, 2014 25

Table 8: Pfizer's Breast Cancer Portfolio Assessment, 2014 27

Table 9: Pfizer SWOT Analysis, 2014 27

Table 10: Novartis' Breast Cancer Portfolio Assessment, 2014 29

Table 11: Novartis SWOT Analysis, 2014 29

Table 12: HER2-Negative Breast Cancer Incidence, 2013-2023 66

Table 13: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer 67

Table 14: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer 68

Table 15: Average Body Weight and Surface Area Across the 8MM 69

Table 16: Cost per Treatment Cycle ($) - Abraxane, Metastatic Setting (HR+) 72

Table 17 Cost per Treatment Cycle ($) - Avastin, Metastatic Setting (HR+/TNBC) 73

Table 18: Cost per Treatment Cycle ($) - Afinitor, Third-Line Hormonal/ Targeted Therapy 74

Table 19: Cost per Treatment Cycle ($) - Doxil, Metastatic Setting (HR+/TNBC) 75

Table 20: Cost per Treatment Cycle ($) - Halaven, Metastatic Setting (HR+/TNBC) 76

Table 21: Cost per Treatment Cycle ($) - Ixempra, Metastatic Setting (HR+/TNBC) 77

Table 22 Cost per Treatment Cycle ($) - Xeloda, Metastatic Setting (HR+/TNBC) 78

Table 23: Cost per Treatment Cycle ($) - Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+) 79

Table 24: Cost per Treatment Cycle ($) - Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+) 80

Table 25: Cost per Treatment Cycle ($) - Javlor, Third-Line Chemotherapy Metastatic Setting (HR+) 81

Table 26: Cost per Treatment Cycle ($) - LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+) 82

Table 27: Cost per Treatment Cycle ($) - NeuVax, Adjuvant Setting (HR+) 83

Table 28: Cost per Treatment Cycle ($) - Niraparib, Metastatic TNBC Setting 83

Table 29: Cost per Treatment Cycle ($) - NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+) 84

Table 30: Cost per Treatment Cycle ($) - Lynparza, Adjuvant and First-Line Metastatic TNBC Settings 85

Table 31: Cost per Treatment Cycle ($) - Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+) 86

Table 32: Cost per Treatment Cycle ($) - Talazoparib, Third-Line Metastatic TNBC Setting 87

Table 33: Cost per Treatment Cycle ($) - Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings 88

Table 34: Physicians Surveyed by Country 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com


Bristol-Myers Squibb

Eli Lilly



select a license
Single User License
USD 2995 INR 214981
Site License
USD 5990 INR 429962
Corporate User License
USD 8985 INR 644943



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com